The undruggable KRAS G12V mutant mRNA can be selectively inhibited by ATB-350.

01Small-Molecule Inhibitor Directly Targeting Mutant KRAS

02Difficulties of Developing KRAS Mutant Inhibitors

• High KRAS-GTP binding affinity (IC50: 10~20 pM)
• Absence of binding interaction site due to mutation
• Difficulty in selectively regulating KRAS mutant

03MoA of KRAS Mutant Selective ASO

04ASO anti-cancer agent with a new MoA that can be administered to incurable patients